BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sarah Aebersold Sells 3,000 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $21.03, for a total value of $63,090.00. Following the completion of the transaction, the insider now directly owns 61,683 shares of the company’s stock, valued at $1,297,193.49. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Sarah Aebersold also recently made the following trade(s):

• On Monday, April 22nd, Sarah Aebersold sold 410 shares of BioLife Solutions stock. The shares were sold at an average price of $16.50, for a total value of $6,765.00.
• On Thursday, April 18th, Sarah Aebersold sold 348 shares of BioLife Solutions stock. The stock was sold at an average price of $15.31, for a total transaction of $5,327.88.

BioLife Solutions Stock Performance

NASDAQ:BLFS opened at $20.03 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.89 and a quick ratio of 1.77. The firm has a market cap of $922.76 million, a PE ratio of -14.11 and a beta of 1.85. The firm has a 50 day simple moving average of $20.51 and a 200-day simple moving average of $18.35. BioLife Solutions, Inc. has a 1-year low of $8.92 and a 1-year high of $23.85.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, May 9th. The medical equipment provider reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.06. BioLife Solutions had a negative return on equity of 12.89% and a negative net margin of 45.84%. The company had revenue of $31.73 million during the quarter, compared to the consensus estimate of $29.30 million. During the same period in the previous year, the firm posted ($0.27) EPS. On average, equities analysts expect that BioLife Solutions, Inc. will post -0.44 EPS for the current year.

Hedge Funds Weigh In On BioLife Solutions

Large investors have recently added to or reduced their stakes in the business. Conestoga Capital Advisors LLC grew its holdings in BioLife Solutions by 1.0% in the 1st quarter. Conestoga Capital Advisors LLC now owns 65,477 shares of the medical equipment provider’s stock valued at $1,215,000 after buying an additional 630 shares during the period. Sei Investments Co. grew its holdings in BioLife Solutions by 1.4% in the first quarter. Sei Investments Co. now owns 60,191 shares of the medical equipment provider’s stock valued at $1,117,000 after purchasing an additional 839 shares during the period. Nisa Investment Advisors LLC raised its stake in BioLife Solutions by 167.2% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 1,020 shares during the period. Price T Rowe Associates Inc. MD raised its stake in BioLife Solutions by 10.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,129 shares of the medical equipment provider’s stock worth $281,000 after purchasing an additional 1,374 shares during the period. Finally, Texas Permanent School Fund Corp boosted its holdings in shares of BioLife Solutions by 4.7% in the 1st quarter. Texas Permanent School Fund Corp now owns 31,145 shares of the medical equipment provider’s stock valued at $578,000 after purchasing an additional 1,384 shares during the last quarter. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. StockNews.com upgraded shares of BioLife Solutions to a “sell” rating in a research report on Friday, May 10th. Benchmark raised BioLife Solutions from a “neutral” rating to a “buy” rating and set a $25.00 target price on the stock in a research note on Monday, May 13th. Finally, Jefferies Financial Group began coverage on BioLife Solutions in a report on Thursday, April 4th. They set a “buy” rating and a $22.00 target price on the stock. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $23.67.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.